Axsome Therapeutics, Inc. (AXSM): Price and Financial Metrics
GET POWR RATINGS... FREE!
AXSM Stock Price Chart Interactive Chart >
AXSM Price/Volume Stats
| Current price | $37.96 | 52-week high | $71.50 |
| Prev. close | $37.03 | 52-week low | $19.38 |
| Day low | $34.68 | Volume | 5,500,700 |
| Day high | $39.73 | Avg. volume | 1,125,397 |
| 50-day MA | $29.27 | Dividend yield | N/A |
| 200-day MA | $32.97 | Market Cap | 1.48B |
Axsome Therapeutics, Inc. (AXSM) Company Bio
Axsome Therapeutics Inc. focuses on developing therapies for the management of pain, neurological disorders, and other central nervous system. The company was founded in 2012 and is based in New York City, New York.
Latest AXSM News From Around the Web
Below are the latest news stories about Axsome Therapeutics Inc that investors may wish to consider to help them evaluate AXSM as an investment opportunity.
Bristol Myers' (BMY) Breyanzi sBLA Gets FDA's Priority ReviewThe FDA accepts Bristol Myers' (BMY) sBLA for Breyanzi under a priority review as a second-line treatment for relapsed/refractory large B-cell lymphoma. A decision is due on Jun 24, 2022. |
Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022Axsome to host conference call and webcast on Tuesday, March 1, 2022 at 8:00 AM Eastern Time |
Axsome Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceNEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a virtual fireside chat at the 11 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 1:40 PM Eastern Time. |
My Top High-Conviction Home Run StockAlthough home run stocks, or equities capable of producing life-altering returns in a short period of time, are far from commonplace, the biopharmaceutical industry has been fertile ground for explosive growth vehicles for a number of years now. While developing pharmaceuticals is fraught with risk at nearly every step, several clinical-stage biotechs have, in fact, overcome these long odds over the past 10 years to bring important new medicines to market. Investors, in turn, ought not overlook the extraordinary risks associated with potential home run plays in the complex world of biopharmaceuticals. |
Deciphera (DCPH) Q4 Loss Wider Than Expected, Revenues BeatDeciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading. |
AXSM Price Returns
| 1-mo | N/A |
| 3-mo | -8.29% |
| 6-mo | 0.48% |
| 1-year | -45.51% |
| 3-year | 47.42% |
| 5-year | 590.18% |
| YTD | 0.48% |
| 2021 | -53.63% |
| 2020 | -21.18% |
| 2019 | 3,565.25% |
| 2018 | -49.64% |
| 2017 | -17.04% |
Loading social stream, please wait...